Results 51 to 60 of about 5,551,009 (351)
Molecular Oncology, 1999 The remarkable specificity of the immune system through antigen recognition has long attracted investigators to the possibility of immune‐based therapy for cancer. Previous cancer immunotherapeutics had been restricted to non‐specific immunomodulatory agents, such as the cytokines IL‐2 or IFN‐α.
openaire +3 more sources
European Journal of Pharmacology, 2009 Major advances have been made in the field of immunology in the past two decades. A better understanding of the molecular and cellular mechanisms controlling the immune system has opened the door to many innovative and promising new cancer therapies that manipulate the immune response.
Hossein, Borghaei +2 more
openaire +2 more sources
Addressing current challenges in cancer immunotherapy with mathematical and computational modeling
, 2017 The goal of cancer immunotherapy is to boost a patient's immune response to a tumor. Yet, the design of an effective immunotherapy is complicated by various factors, including a potentially immunosuppressive tumor microenvironment, immune-modulating ...
Adler, Adam J. +3 more
core +1 more source
Immunological backbone of uveal melanoma: is there a rationale for immunotherapy? [PDF]
, 2019 No standard treatment has been established for metastatic uveal melanoma (mUM). Immunotherapy is commonly used for this disease even though UM has not been included in phase III clinical trials with checkpoint inhibitors.
Alessandra Cassano +24 more
core +1 more source
Recent advances in nanomedicines for photodynamic therapy (PDT)-driven cancer immunotherapy
Theranostics, 2022 Cancer immunotherapy has made tremendous clinical progress in advanced-stage malignancies. However, patients with various tumors exhibit a low response rate to immunotherapy because of a powerful immunosuppressive tumor microenvironment (TME) and ...
Bin Ji, Minjie Wei, Bin Yang
semanticscholar +1 more source
Nivolumab-induced fulminant diabetic ketoacidosis followed by thyroiditis [PDF]
, 2018 Five days following the 3rd cycle of nivolumab, a monoclonal antibody, which acts as immune checkpoint inhibitor against the programmed cell death protein-1, for metastatic lung adenocarcinoma, a 56-year-old woman presented at the hospital critically ill.
Baker, E +6 more
core +2 more sources
Journal for ImmunoTherapy of Cancer, 2019 Background High-affinity tumor antigen-specific T-cell receptor (TCR) gene is required to engineer potent T cells for therapeutic treatment of cancer patients.
Junko Matsuzaki +5 more
doaj +1 more source
The Evolving Role of CD8+CD28- Immunosenescent T Cells in Cancer Immunology [PDF]
, 2019 Functional, tumor-specific CD8+ cytotoxic T lymphocytes drive the adaptive immune response to cancer. Thus, induction of their activity is the ultimate aim of all immunotherapies.
Dey, Mahua +4 more
core +1 more source
Exploiting innate immunity for cancer immunotherapy
Molecular Cancer, 2023 Immunotherapies have revolutionized the treatment paradigms of various types of cancers. However, most of these immunomodulatory strategies focus on harnessing adaptive immunity, mainly by inhibiting immunosuppressive signaling with immune checkpoint ...
Ming Yi +7 more
semanticscholar +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Pediatric gastroenteropancreatic neuroendocrine neoplasms (GEP‐NENs) are extremely rare and clinically heterogeneous. Management has largely been extrapolated from adult practice. This European Standard Clinical Practice Guideline (ESCP), developed by the EXPeRT network in collaboration with adult NEN experts, provides (adult) evidence ...
Michaela Kuhlen +23 more
wiley +1 more source